CA2465916A1 - Treatment of breast cancer - Google Patents

Treatment of breast cancer Download PDF

Info

Publication number
CA2465916A1
CA2465916A1 CA002465916A CA2465916A CA2465916A1 CA 2465916 A1 CA2465916 A1 CA 2465916A1 CA 002465916 A CA002465916 A CA 002465916A CA 2465916 A CA2465916 A CA 2465916A CA 2465916 A1 CA2465916 A1 CA 2465916A1
Authority
CA
Canada
Prior art keywords
patients
breast cancer
patient
treatment
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465916A
Other languages
English (en)
French (fr)
Inventor
Mark Vincent
Lorne J. Brandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Gilead YM ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2465916A1 publication Critical patent/CA2465916A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002465916A 2001-11-09 2002-11-06 Treatment of breast cancer Abandoned CA2465916A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33114201P 2001-11-09 2001-11-09
US60/331,142 2001-11-09
US40724102P 2002-09-03 2002-09-03
US60/407,241 2002-09-03
PCT/CA2002/001725 WO2003039526A1 (en) 2001-11-09 2002-11-06 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
CA2465916A1 true CA2465916A1 (en) 2003-05-15

Family

ID=26987607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465916A Abandoned CA2465916A1 (en) 2001-11-09 2002-11-06 Treatment of breast cancer

Country Status (5)

Country Link
US (1) US20050119263A1 (https=)
EP (1) EP1441711A1 (https=)
JP (1) JP2005512996A (https=)
CA (1) CA2465916A1 (https=)
WO (1) WO2003039526A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003269621A1 (en) * 2002-09-03 2004-03-29 Lorne J. Brandes Neoadjuvant treatment of breast cancer
CA2497180A1 (en) * 2002-09-04 2004-03-18 The University Of Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
CN1703212A (zh) * 2002-09-11 2005-11-30 马尼托巴大学 Dppe与其它化学治疗剂联合治疗乳腺癌的用途
WO2010118782A1 (en) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
US20110195848A1 (en) * 2010-01-08 2011-08-11 Roopra Avtar S Gene expression and breast cancer
BR112017015013A2 (pt) 2015-01-19 2018-01-23 Belina Pharma Ab anti-histamina para uso no tratamento de câncer da mama

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1229604A (en) * 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
US5798339A (en) * 1990-12-17 1998-08-25 University Of Manitoba Treatment method for cancer
US5618846A (en) * 1990-12-17 1997-04-08 University Of Manitoba Treatment method for cancer
ES2063574T3 (es) * 1990-12-17 1995-01-01 Univ Manitoba Metodo de tratamiento mejorado para el cancer.
US6284799B1 (en) * 1994-02-17 2001-09-04 University Of Manitoba Cancer treatment

Also Published As

Publication number Publication date
JP2005512996A (ja) 2005-05-12
WO2003039526A1 (en) 2003-05-15
US20050119263A1 (en) 2005-06-02
EP1441711A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
Kopf et al. Clinical management of malignant adrenal tumors
Jain Cardiotoxicity of doxorubicin and other anthracycline derivatives
Monnerat et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers
Motzer et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Warner et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
CA2465916A1 (en) Treatment of breast cancer
Saeter et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study
WO2022150851A2 (en) Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
AU2002340668A1 (en) Treatment of breast cancer
Padhye et al. Chemotherapy regimens in newly diagnosed and recurrent Ewing sarcoma in children and young adults
Andreyev et al. Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF)
EP1605951A1 (en) Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor
Dreicer et al. Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup
Metzger Adjuvant therapy for colorectal carcinoma
US20060142287A1 (en) Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
US20080318880A1 (en) Neoadjuvant treatment of Breast Cancer
Hurteloup et al. Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
KR20080034151A (ko) 암 치료를 위한 조스퀴다르, 다우노루비신 및 시타라빈
Casper et al. Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma
US20060089317A1 (en) Treatment of metastatic breast cancer with anthracyclines, and taxanes
Csekeõ Current state of surgery for small cell lung cancer
WO2004022044A1 (en) Use of a combination of a taxane with dppe for the treatment of cancer
Utsumi et al. Elimination of pancoast tumor by carboplatin, paclitaxel, and concurrent radiation
Speyer Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy
WO2010014250A1 (en) Prediction of cancer therapy based on cathespin b levels

Legal Events

Date Code Title Description
FZDE Discontinued